The Role of L-arginine in Polycystic Ovary Syndrome

Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · Dec 8, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a supplement called L-arginine on women with Polycystic Ovary Syndrome (PCOS). PCOS is a common condition that can affect a woman's hormone levels, menstrual cycle, and overall health. The study aims to see if taking L-arginine can help improve symptoms of PCOS and if it is safe to use. Participants will be recruited from the Shanghai 10th People's Hospital and will undergo various evaluations including laboratory tests and follow-ups after taking the supplement.

To be eligible for this trial, women must be between the ages of 18 and 45 and have a confirmed diagnosis of PCOS. However, those who are pregnant, have certain thyroid or severe health conditions, or have been on specific medications or treatments for PCOS recently cannot participate. If you join the trial, you can expect to receive L-arginine and be monitored closely to assess how well it works for you. This is a great opportunity for women looking for new treatment options for PCOS, as researchers are dedicated to understanding how this supplement may help manage the condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • aged 18-45 years
• • Diagnosis of PCOS with the Rotterdam diagnosis criteria (2003)
• Exclusion Criteria:
• • Pregnant women;
• • Hyperthyroidism or hypothyroidism
• • Severe liver and kidney function injury
• • Cancer patients;
• • Associated with severe infection, severe anemia, neutropenia and other blood system diseases;
• • Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes;
• • Patients with mental illness or intellectual disability;
• • Have a long history of taking hormone therapy;
• • Currently or recently participating in another clinical trial.